title: Tight Junction Protein 1: New Insights into Proteasome Inhibitor Resistance and Myeloma Pathophysiology.
abstract: In this issue of Cancer Cell, Zhang et al. report that TJP1 suppresses EGFR/JAK1/STAT3-mediated signaling and increases the proteasome inhibitor sensitivity of myeloma cells by altering the cellular proteasome capacity versus proteasome load of undegraded intracellular proteins.
authors.affiliation: Department of Medical Oncology, Dana-Farber Cancer Institute and Department of Medicine, Harvard Medical School, Boston, MA 02215, USA. Electronic address: constantine_mitsiades@dfci.harvard.edu.
authors.forename: Constantine S
authors.initials: CS
authors.lastname: Mitsiades
mesh_terms: D001897:Boronic Acids; D000069286:Bortezomib; D045744:Cell Line, Tumor; D006801:Humans; D009101:Multiple Myeloma / Q000378:metabolism; D046988:Proteasome Endopeptidase Complex / Q000378:metabolism; D061988:Proteasome Inhibitors / Q000494:pharmacology*; D062826:Zonula Occludens-1 Protein
chemical_list: D001897:Boronic Acids; D061988:Proteasome Inhibitors; D062826:Zonula Occludens-1 Protein; D000069286:Bortezomib; D046988:Proteasome Endopeptidase Complex